CLINICAL TRIAL RECRUITING PATIENT

No.

Ongoing Studies

Investigator

Study Code: D926QC00001 Study Title: A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato DXd)Plus Durvalumab Followed by Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or Hormone Receptor low/HER2-negative Breast Cancer (D926QC00001; TROPION Breast04))

Dr. Deepak Gupta

Study Code: D7984C00002 Study Title: A Phase III, Randomized, Double blind, Placebo controlled, Multi centre, Global Study of Volrustomig in Women with High Risk Locally Advanced Cervical Cancer Who Have Not Progressed Following Platinum based, Concurrent Chemoradiation Therapy (eVOLVE Cervical).

Dr. Deepak Gupta

Study Title “A Prospective, Multicenter, Open-label, Phase IV, Interventional Study to Assess the Safety and Efficacy of Capmatinib in Indian Patients with Mesenchymal-Epithelial Transition (MET) exon 14 Skipping Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)”.

Dr. Deepak Gupta

Study Code: D926NC00001 Study Title: A Phase III, Randomised, Open-label, Multicentre, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab and Carboplatin Versus Pembrolizumab in Combination With Platinum-based Chemotherapy for the First line Treatment of Patients With Locally Advanced or Metastatic NSCLC Without Actionable Genomic Alterations (D926NC00001; AVANZAR):

Dr. Deepak Gupta

Protocol Number #: R3918-PNH-2021Protocol: A Randomized, Open-Label,C5 Inhibitor-Controlled Study to Evaluate the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Patients with Paroxysmal Nocturnal Hemoglobinuria who are Complement Inhibitor Treatment-Naive or Have Not Recently Received Complement Inhibitor Therapy..

Dr. Upendra Sharma

Protocol title: Study Code: D9075C00001, Study Title: A Phase III, Randomised, Double blind, Placebo controlled, Multicentre, International Study of Durvalumab plus Domvanalimab (AB154) in Participants with Locally Advanced (Stage III), Unresectable Non-Small Cell Lung Cancer Whose Disease has not Progressed Following Definitive Platinum based Concurrent Chemo-radiation Therapy (PACIFIC-8)

Dr. Aseem K Samar

Protocol title: Protocol#:21707 Protocol: A single-arm, open-label Phase 4 study of darolutamide in addition to standard androgen deprivation therapy for participants in Indian with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC)

Dr. Aseem K Samar

Protocol title: Study Code: D361DC00001 Study Title: A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292)

Dr. Aseem K Samar

Study Code: D9319C00001 Study Title: A Randomised, Double-blind, Placebo-controlled, Phase III Study of Olaparib Maintenance Monotherapy in Participants with BRCA Wild Type Advanced (FIGO Stage III-IV) High Grade Serous or Endometrioid Ovarian Cancer Following Response to Standard First-line Platinum-based Chemotherapy (MONO-OLA1)

Dr. Deepak Gupta

Protocol Entitled: A Phase 3, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator’s Choice Chemotherapy in HER2-low, Hormone Receptor Positive Breast Cancer Patients whose Disease has Progressed on Endocrine Therapy in the Metastatic Setting DESTINY-Breast06)

Dr. Deepak Gupta

A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide in addition to androgen deprivation therapy (ADT) versus placebo plus ADT in men with metastatic hormone- sensitive prostate cancer (mHSPC)

Dr. Pawan Agarwal